Kalorama Report: Sizable Number of Acquisitions and Joint Ventures in Molecular Diagnostics - KPTV - FOX 12

Kalorama Report: Sizable Number of Acquisitions and Joint Ventures in Molecular Diagnostics

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Kalorama Information

NEW YORK, Aug. 12, 2014 /PRNewswire/ -- Molecular diagnostic companies are partnering to survive, according to a recent Kalorama Information report.  The healthcare market research publisher said that the 5.5 billion dollar molecular diagnostics market grew by combination last year, where possible partnerships were formed and in some cases outright purchases.  The report said numerous acquisitions and joint ventures occurred in 2013 and will change the market today.   

Kalorama Information Logo

The finding was made in Kalorama's The World Market for Molecular Diagnostics Update, the firm's latest look at the molecular IVD segment that can be found at: http://www.marketresearch.com/redirect.asp?progid=86503&url=http%3A%2F%2Fwww%2Ekaloramainformation%2Ecom%2FMolecular%2DDiagnostics%2DMonth%2D7969379%2F.

"A dynamic market encourages players to bolster their offerings with acquisitions, collaborations and licensing agreements," said Shara Rosen, Kalorama analyst and author of the report.

The report said the complexity of molecular testing encourages companies to augment their capabilities via collaborations and licensing agreements. Examples include:

  • Exosome Diagnostics U.S. with Eli Lilly, cancer PGx
  • Illumina U.S. with Global Genomics cardiac markers
  • Life Technologies/Thermo Fisher U.S. with Merck Serono drug PG

Collaboration is not always possible with companies remaining independent entities and thus many companies made purchase to cover gaps in expertise.  Kalorama cited the following as examples of 17 significant 2013 purchases where IVD companies acquired molecular dx startups or small concerns.

  • bioMerieux's purchase of BioFire Diagnostics
  • Grifol's purchase of Novartis's blood bank testing
  • Illumina's continued expansion into clinical markets (Next Bio, Advanced Liquid Logic)
  • Qiagen's purchase of CLC Bio.
  • Sysmex's purchase of Inostics digital PCR from Indivumed

Kalorama goes into greater detail about these combinations in its report, The World Market for Molecular Diagnostics Update.   Market analysis in the covers world markets for in vitro diagnostics, particularly North America and Western Europe. Segment markets within molecular diagnostics are broken out, and trends and partnerships are given extensive discussion.

About Kalorama Information -- Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog.

Contact:
Bruce Carlson
(212) 807-2622
bcarlson@kaloramainformation.com

Logo - http://photos.prnewswire.com/prnh/20140801/132634

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow
FOX 12
Powered by WorldNow CNN
All content © 2014, KPTV-KPDX Broadcasting Corporation, Portland, OR and WorldNow. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.